The KardioPal three-lead ECG reconstructive technology demonstrated high diagnostic accuracy (96.1%), sensitivity (95.8%), and specificity (96.3%) compared to standard 12-lead ECG.
Observational (n=102)
Adjudicator-blinded
No
Does the KardioPal three-lead ECG reconstructive technology provide comparable diagnostic accuracy to a standard 12-lead ECG in patients evaluated during the COVID-19 pandemic?
A novel three-lead ECG reconstructive technology (KardioPal) offers high diagnostic accuracy compared to standard 12-lead ECGs, potentially reducing acquisition time and healthcare burden.
The 12-lead electrocardiogram (ECG) is a first-line diagnostic tool for patients with cardiac symptoms. As observed during the COVID-19 pandemic, the ECG is essential to the initial patient evaluation. The novel KardioPal three-lead-based ECG reconstructive technology provides a potential alternative to a standard ECG, reducing the response time and cost of treatment and improving patient comfort. Our study aimed to evaluate the diagnostic accuracy of a reconstructed 12-lead ECG obtained by the KardioPal technology, comparing it with the standard 12-lead ECG, and to assess the feasibility and time required to obtain a reconstructed ECG in a real-life scenario. A prospective, nonrandomized, single-center, adjudicator-blinded trial was conducted on 102 patients during the COVID-19 pandemic at the Dedinje Cardiovascular Institute in Belgrade. The KardioPal system demonstrated a high feasibility rate (99%), with high specificity (96.3%), sensitivity (95.8%), and diagnostic accuracy (96.1%) for obtaining clinically relevant matching of reconstructed 12-lead compared to the standard 12-lead ECG recording. This novel technology provided a significant reduction in ECG acquisition time and the need for personnel and space for obtaining ECG recordings, thereby reducing the risk of viral transmission and the burden on an already overwhelmed healthcare system such as the one experienced during the COVID-19 pandemic.
Babić et al. (Fri,) conducted a observational in Cardiac symptoms (n=102). KardioPal three-lead-based ECG reconstructive technology vs. Standard 12-lead ECG was evaluated on Diagnostic accuracy of reconstructed 12-lead ECG compared to standard 12-lead ECG. The KardioPal three-lead ECG reconstructive technology demonstrated high diagnostic accuracy (96.1%), sensitivity (95.8%), and specificity (96.3%) compared to standard 12-lead ECG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: